https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 Interactive effects of polygenic risk and cognitive subtype on brain morphology in schizophrenia spectrum and bipolar disorders https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51035 Wed 16 Aug 2023 10:17:09 AEST ]]> Multivariate neuroanatomical classification of cognitive subtypes in schizophrenia: a support vector machine learning approach https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:19873 Wed 11 Apr 2018 15:32:27 AEST ]]> New South Wales child development study (NSW-CDS): an Australian multiagency, multigenerational, longitudinal record linkage study https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:24528 Wed 11 Apr 2018 15:24:21 AEST ]]> The 2015 Middle Childhood Survey (MCS) of mental health and well-being at age 11 years in an Australian population cohort https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:30220 Wed 11 Apr 2018 15:10:52 AEST ]]> No reliable association between runs of homozygosity and schizophrenia in a well-powered replication study https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27630 Froh and schizophrenia (β = 4.86,CI(β) = [0.90,8.83],Z = 2.40,p = 0.02). Since Keller et al. (2012), several studies reported inconsistent association of ROH burden with complex traits, particularly in case-control data. These conflicting results might suggest that the effects of autozygosity are confounded by various factors, such as socioeconomic status, education, urbanicity, and religiosity, which may be associated with both real inbreeding and the outcome measures of interest.]]> Wed 11 Apr 2018 14:15:34 AEST ]]> Application of the audio recorded cognitive screen and its relation to functioning in schizophrenia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:28274 2(1)=7.16, p=0.007]. Conclusion: The ARCS may be sensitive to the cognitive deficits in outpatients with schizophrenia and an indicator of functional outcomes in this population.]]> Wed 11 Apr 2018 13:05:57 AEST ]]> Ten-year audit of clients presenting to a specialised service for young people experiencing or at increased risk for psychosis https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:16754 Wed 11 Apr 2018 10:51:14 AEST ]]> Randomized controlled trial of MICBT for co-existing alcohol misuse and depression: outcomes to 36-months https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13769 Wed 11 Apr 2018 10:20:22 AEST ]]> Transcriptome sequencing revealed significant alteration of cortical promoter usage and splicing in schizophrenia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15118 Wed 11 Apr 2018 09:18:27 AEST ]]> Common variation in ZNF804A (rs1344706) is not associated with brain morphometry in schizophrenia or healthy participants https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43092 C] within intron 2 of the zinc finger protein 804A gene (ZNF804A) is associated with schizophrenia at the genome-wide level, but its function in relation to the development of psychotic disorders, including its influence on brain morphology remains unclear. Methods: Using both univariate (voxel-based morphometry, VBM; cortical thickness) and multivariate (source-based morphometry, SBM) approaches, we examined the effects of variation of the rs1344706 polymorphism on grey matter integrity in 214 Caucasian schizophrenia cases and 94 Caucasian healthy individuals selected from the Australian Schizophrenia Research Bank. Results: Neither univariate nor multivariate analyses showed any associations between indices of grey matter and rs1344706 variation in schizophrenia or healthy participants. This was revealed in the context of the typical pattern of decreased grey matter integrity in schizophrenia compared to healthy individuals, including: (1) large grey matter volume reductions in the orbitofrontal and anterior cingulate cortices and the left fusiform/inferior temporal gyri; (2) decreased cortical thickness in the left inferior temporal and fusiform gyri, the left orbitofrontal gyrus, as well as in the right pars opercularis/precentral gyrus; and (3) decreased covariation of grey matter concentration in frontal and limbic brain regions emerging from the SBM analyses. Conclusions: Contrary to some – but not all – previous findings, this study of a large sample of schizophrenia cases and healthy controls reveals no evidence for association between grey matter alterations and variation in rs1344706 (ZNF804A). Differences in sample sizes and ethnicities may account for discrepant findings between the present and previous studies.]]> Wed 07 Jun 2023 14:36:02 AEST ]]> Impact of rurality and substance use on young people at ultra-high risk for psychosis https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36084 Wed 05 Feb 2020 14:23:07 AEDT ]]> Utility of risk-status for predicting psychosis and related outcomes: evaluation of a 10-year cohort of presenters to a specialised early psychosis community mental health service https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:33211 without (35.4%, the reference group) and with psychiatric admissions (8.3%); and incomplete assessments (12.5%). High comorbidity levels were reported by the cohort (psychosocial problems, 61.1%; depression, 54.1%; substance misuse, 40.7%). UHR clients experienced similar psychosis transition rates to the reference group (17.3% vs. 14.6%; 8.9% vs. 9.1% within 2-years) and comparable rates of subsequent non-psychosis outcomes. A 25.9% conversion rate from early psychosis to schizophrenia was detected. However, among transitioning individuals, UHR clients faired relatively better, particularly with respect to changes in comorbidity and mental health contacts. Interventions tailored to current problems, recovery and psychological strengthening may be more appropriate than those based on estimated psychosis risk, which currently lacks clinical utility.]]> Wed 04 Sep 2019 10:05:29 AEST ]]> Alteration of DNA Methylation and Epigenetic Scores Associated with Features of Schizophrenia and Common Variant Genetic Risk https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55024 Wed 03 Apr 2024 15:41:54 AEDT ]]> Cohort Profile: The New South Wales Child Development Study (NSW-CDS)-Wave 2 (child age 13 years) https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36604 Tue 30 Aug 2022 15:06:47 AEST ]]> The maternal immune activation model uncovers a role for the Arx gene in GABAergic dysfunction in schizophrenia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44959 Arx gene, critical to healthy neurodevelopment of PV interneurons, is reduced in the forebrain of MIA exposed mice. Finally, in a whole-genome sequenced patient cohort, we identified a novel missense mutation of ARX in a patient with schizophrenia and in the Psychiatric Genomics Consortium 2 cohort, a nominal association of proximal ARX SNPs with the disorder. This suggests MIA, as a risk factor for schizophrenia, may be influencing Arx expression to induce the GABAergic dysfunction seen in schizophrenia and that the ARX gene may play a role in the prenatal origins of schizophrenia pathophysiology.]]> Tue 25 Oct 2022 12:28:24 AEDT ]]> Complement genes contribute sex-biased vulnerability in diverse disorders https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38872 1, whereas schizophrenia affects men with greater frequency and severity relative to women2. All three illnesses have their strongest common genetic associations in the major histocompatibility complex (MHC) locus, an association that in SLE and Sjögren’s syndrome has long been thought to arise from alleles of the human leukocyte antigen (HLA) genes at that locus3,4,5,6. Here we show that variation of the complement component 4 (C4) genes C4A and C4B, which are also at the MHC locus and have been linked to increased risk for schizophrenia7, generates 7-fold variation in risk for SLE and 16-fold variation in risk for Sjögren’s syndrome among individuals with common C4 genotypes, with C4A protecting more strongly than C4B in both illnesses. The same alleles that increase risk for schizophrenia greatly reduce risk for SLE and Sjögren’s syndrome. In all three illnesses, C4 alleles act more strongly in men than in women: common combinations of C4A and C4B generated 14-fold variation in risk for SLE, 31-fold variation in risk for Sjögren’s syndrome, and 1.7-fold variation in schizophrenia risk among men (versus 6-fold, 15-fold and 1.26-fold variation in risk among women, respectively). At a protein level, both C4 and its effector C3 were present at higher levels in cerebrospinal fluid and plasma8,9 in men than in women among adults aged between 20 and 50 years, corresponding to the ages of differential disease vulnerability. Sex differences in complement protein levels may help to explain the more potent effects of C4 alleles in men, women’s greater risk of SLE and Sjögren’s syndrome and men’s greater vulnerability to schizophrenia. These results implicate the complement system as a source of sexual dimorphism in vulnerability to diverse illnesses.]]> Tue 22 Feb 2022 16:36:25 AEDT ]]> Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:34283 −15), which persisted after excluding loci implicated in previous studies (OR = 1.07, P = 1.7 × 10−6). CNV burden was enriched for genes associated with synaptic function (OR = 1.68, P = 2.8 × 10−11) and neurobehavioral phenotypes in mouse (OR = 1.18, P = 7.3 × 10−5). Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate susceptibility and protective loci, which consisted predominantly of CNVs mediated by nonallelic homologous recombination.]]> Tue 03 Sep 2019 18:30:49 AEST ]]> Pharmacological enrichment of polygenic risk for precision medicine in complex disorders https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41990 Thu 10 Aug 2023 12:12:50 AEST ]]> Aggression and trauma experiences among carer-relatives of people with psychosis https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7405 Sat 24 Mar 2018 08:42:43 AEDT ]]> Measuring observed mental state in acute psychiatric inpatients https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8285 Sat 24 Mar 2018 08:40:28 AEDT ]]> Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7057 Sat 24 Mar 2018 08:38:04 AEDT ]]> Smoking restrictions and treatment for smoking: policies and procedures in psychiatric inpatient units in Australia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8091 Sat 24 Mar 2018 08:34:27 AEDT ]]> Comparisons between schizophrenia patients recruited from Australian general practices and public mental health services https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1546 Sat 24 Mar 2018 08:30:43 AEDT ]]> Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1649 Sat 24 Mar 2018 08:30:38 AEDT ]]> A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1024 Sat 24 Mar 2018 08:29:47 AEDT ]]> Long-term follow-up of people with co-existing psychiatric and substance use disorders: patterns of use and outcomes https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1170 Sat 24 Mar 2018 08:28:44 AEDT ]]> Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1164 Sat 24 Mar 2018 08:28:43 AEDT ]]> Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1486 Sat 24 Mar 2018 08:28:04 AEDT ]]> Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1806 Sat 24 Mar 2018 08:27:29 AEDT ]]> Drug use patterns and mental health of regular ampthetamine users during a reported 'heroin drought' https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1695 Sat 24 Mar 2018 08:27:20 AEDT ]]> Recovery from post-earthquake psychological morbidity: who suffers and who recovers? https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:2794 Sat 24 Mar 2018 08:27:06 AEDT ]]> The psychological impact of chronic environmental adversity: responding to prolonged drought https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15423 Sat 24 Mar 2018 08:23:01 AEDT ]]> Determinants of mental health and well-being within rural and remote communities https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:12389 Sat 24 Mar 2018 08:18:01 AEDT ]]> Clinical indicators for routine use in the evaluation of early psychosis intervention: development, training support and inter-rater reliability https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13271 0.65). Inspection of contingency tables (coding category by health service) and modal scores across services suggested consistent, unbiased coding across services. Clinicians are able to agree upon what information is essential to routinely evaluate clinical practice. Simple indicators of this information can be designed and coding rules can be reliably applied to written vignettes after brief training. The real world feasibility of the indicators remains to be tested in field trials.]]> Sat 24 Mar 2018 08:15:16 AEDT ]]> Cerebellar grey matter deficits in first-episode schizophrenia mapped using cortical pattern matching https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10763 Sat 24 Mar 2018 08:13:54 AEDT ]]> Pathways to care and community-based service contact patterns among clients with a dual diagnosis https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10601 Sat 24 Mar 2018 08:13:49 AEDT ]]> Intervention for cannabis use in young people at ultra high risk for psychosis and in early psychosis https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10627 Sat 24 Mar 2018 08:13:48 AEDT ]]> Randomized controlled trial of cognitive-behavioural therapy for coexisting depression and alcohol problems: short-term outcome https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10936 Sat 24 Mar 2018 08:13:21 AEDT ]]> Beauty and belief: William James and the aesthetics of delusions in schizophrenia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10996 Sat 24 Mar 2018 08:12:41 AEDT ]]> Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approaches https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10461 Sat 24 Mar 2018 08:09:12 AEDT ]]> Is a national framework for implementing early psychosis services necessary? results of a survey of Australian mental health service directors https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10890 Sat 24 Mar 2018 08:09:02 AEDT ]]> Mental health and well-being within rural communities: The Australian Rural Mental Health Study https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10373 Sat 24 Mar 2018 08:08:50 AEDT ]]> Brief neuropsychological profiles in psychosis: a pilot study using the Audio Recorded Cognitive Screen (ARCS) https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10315 Sat 24 Mar 2018 08:07:00 AEDT ]]> Catechol-O-methyltransferase (COMT) genotype moderates the effects of childhood trauma on cognition and symptoms in schizophrenia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:21387 Catechol-O-methyltransferase (COMT) Val158Met polymorphism, a common genetic variant known to affect cognition and prefrontal dopamine levels. Participants were 429 schizophrenia/schizoaffective cases from the Australian Schizophrenia Research Bank (ASRB). Cognitive performance was assessed using the Repeatable Battery for Assessment of Neuropsychological Status (RBANS), Controlled Oral Word Association Test (COWAT), Letter Number Sequencing (LNS) test, and the Wechsler Test of Adult Reading (WTAR). Hierarchical regression was used to test the main effects and additive interaction effects of genotype and childhood trauma in the domains of physical abuse, emotional abuse, and emotional neglect, on cognition and symptom profiles of clinical cases. Consistent with previous findings, COMT Val homozygotes performed worse on cognitive measures in the absence of childhood adversity. In addition, a significant interaction between COMT genotype and physical abuse was associated with better executive function in Val homozygotes, relative to those of the same genotype with no history of abuse. Finally, the severity of positive symptoms was greater in Met carriers who had experienced physical abuse, and the severity of negative symptoms in Met carriers was greater in the presence of emotional neglect. These results suggest that the possible epigenetic modulation of the expression of the COMT Val158Met polymorphism and consequent effects on cognition and symptoms in schizophrenia, with worse outcomes associated with adverse childhood experiences in Met carriers.]]> Sat 24 Mar 2018 08:05:04 AEDT ]]> What difference a decade? The costs of psychosis in Australia in 2000 and 2010: comparative results from the first and second Australian national surveys of psychosis https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18308 Sat 24 Mar 2018 08:04:40 AEDT ]]> Comparing algorithms for deriving psychosis diagnoses from longitudinal administrative clinical records https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:19532 Sat 24 Mar 2018 08:02:05 AEDT ]]> Biological insights from 108 schizophrenia-associated genetic loci https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:21465 DRD2 and several genes involved in glutamatergic neurotransmission highlight molecules of known and potential therapeutic relevance to schizophrenia, and are consistent with leading pathophysiological hypotheses. Independent of genes expressed in brain, associations were enriched among genes expressed in tissues that have important roles in immunity, providing support for the speculated link between the immune system and schizophrenia.]]> Sat 24 Mar 2018 07:52:31 AEDT ]]> Adverse incidents in acute psychiatric inpatient units: rates, correlates and pressures https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:5339 Sat 24 Mar 2018 07:45:55 AEDT ]]> Assessing cost-effectiveness of drug interventions for schizophrenia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:370 Sat 24 Mar 2018 07:42:30 AEDT ]]> Differential response to risperidone in schizophrenia patients by KCNH2Genotype and drug metabolizer status https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:29401 KCNH2. Variable patient responses and a wide range of side effects, however, limit their efficacy. Slow metabolizer status and gene variants in KCNH2 associated with increased expression of Kv11.1-3.1, an alternatively spliced isoform of Kv11.1, are correlated with improved responses to antipsychotic medications. Here, the authors test the hypothesis that these effectsmaybeinfluencedby differential drug binding to Kv11.1 channel isoforms. Method: Drug block of Kv11.1 isoforms was tested in cellular electrophysiology assays. The effects of drug metabolism and KCNH2 genotypes on clinical responses were assessed in patients enrolled in the multicenter Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Results: Risperidone caused greater in vitro block of the alternatively spliced Kv11.1-3.1 isoform than full-length Kv11.1-1A channels, whereas its metabolite paliperidone and other atypical antipsychotics have similar potencies for the two isoforms. In the CATIE study (N=362), patients with genotypes associated with increased Kv11.1-3.1 expression (N=52) showed a better treatment response to risperidone compared with other drugs, but this association was dependent on metabolism status. Patients with KCNH2 risk genotypes and slow metabolizer status (approximately 7% of patients) showed marked improvement in symptoms when treated with risperidone compared with patients with fast metabolizer status or without the KCNH2 risk genotypes. Conclusions: These data support the hypothesis that Kv11.1 channels play a role in the therapeutic action of antipsychotic drugs, particularly risperidone, and further highlight the promise of optimizing response with genotype-guided therapy for schizophrenia patients.]]> Sat 24 Mar 2018 07:36:19 AEDT ]]> Shift climate profiles and correlates in acute psychiatric inpatient units https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27811 Sat 24 Mar 2018 07:31:12 AEDT ]]> Hospital admission for infection during early childhood influences developmental vulnerabilities at age 5 years https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:29029 Sat 24 Mar 2018 07:31:07 AEDT ]]> Relationship between childhood adversity and clinical and cognitive features in schizophrenia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22081 Sat 24 Mar 2018 07:15:15 AEDT ]]> Altered neural signaling and immune pathways in peripheral blood mononuclear cells of schizophrenia patients with cognitive impairment: a transcriptome analysis https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:25081 Sat 24 Mar 2018 07:15:04 AEDT ]]> Wnt receptor gene FZD1 was associated with schizophrenia in genome-wide SNP analysis of the Australian Schizophrenia Research Bank cohort https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44131 Sat 08 Oct 2022 12:36:32 AEDT ]]> Validation of a two-factor model of the Best Start Kindergarten Assessment of literacy and numeracy https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47465 Mon 23 Jan 2023 10:30:30 AEDT ]]> The MIR137 VNTR rs58335419 Is Associated with Cognitive Impairment in Schizophrenia and Altered Cortical Morphology https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46407 n = 299) and healthy controls (n = 131), we observed that the MIR137 4-repeats VNTR (VNTR4) variant was enriched in a cognitive deficit subtype of schizophrenia and associated with altered brain morphology, including thicker left inferior temporal gyrus and deeper right postcentral sulcus. These findings suggest that the MIR137 VNTR4 may impact neuroanatomical development that may, in turn, influence the expression of more severe cognitive symptoms in patients with schizophrenia.]]> Mon 21 Nov 2022 11:38:46 AEDT ]]> A polygenic resilience score moderates the genetic risk for schizophrenia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38229 Mon 16 Aug 2021 17:39:39 AEST ]]> Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50980 Mon 14 Aug 2023 15:24:38 AEST ]]> Perceptions of causal attribution and attitudes to genetic testing among people with schizophrenia and their first-degree relatives https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50953 Mon 14 Aug 2023 14:36:26 AEST ]]> Polygenic disruption of retinoid signalling in schizophrenia and a severe cognitive deficit subtype https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48305 Mon 01 May 2023 15:23:00 AEST ]]> Connection to the natural environment and well-being in middle childhood https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:35591 Fri 31 Jan 2020 12:59:09 AEDT ]]> Item response theory analysis of the big five questionnaire for children– short form (BFC-SF): A self-report measure of personality in children aged 11–12 years https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:40718 Fri 23 Jun 2023 09:07:27 AEST ]]> Genetic estimates of correlation and causality between blood-based biomarkers and psychiatric disorders https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51745 Fri 15 Sep 2023 18:22:09 AEST ]]> Alteration of miRNA-mRNA interactions in lymphocytes of individuals with schizophrenia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37045 Fri 07 Aug 2020 14:34:14 AEST ]]>